Allergies and asthma are among the most common chronic conditions globally, ranging from manageable to life-threatening. Allergies in particular are on the rise: in 2015 close to 50% of the world population was affected by some form of allergy, while severe allergic reactions (anaphylaxis) have increased several-fold in the past decade.
Allergic rhinitis is one form of allergy and is considered a global epidemic, affecting some 500 million people worldwide, of which around 180 million are in Western Europe, US and Japan. The disease is associated with high socioeconomic costs.
Asthma is a chronic condition affecting the respiratory tract and lungs. It narrows the airways to the lungs due to inflammation in the air passages, resulting from both generic and environmental influences. It is the most common chronic disease among children and an estimated 300 million individuals worldwide are affected.
The cornerstone in asthma therapy is effectively treating the underlying chronic inflammation with inhaled corticosteroids while minimizing systemic exposure. Optimal drug delivery to the lungs is therefore of paramount importance and can be facilitated by spacers. US asthma guidelines have recommended using a spacer for inhaled corticosteroid therapy.